Vascular lasers treat redness, visible blood vessels, rosacea, port-wine stains, and related conditions by targeting hemoglobin in blood vessels. Two platforms dominate this category: the Candela Vbeam family (pulsed dye laser, or PDL) and the Cutera Excel V family (dual-wavelength KTP/Nd:YAG). Both are FDA-cleared, both have years of clinical data, and both are effective — but they work by different mechanisms, reach different depths, and have distinct safety and comfort profiles.
The question is not which one is "better." It is which one matches the patient's specific vascular concern, skin type, and tolerance for downtime.
How vascular lasers work: the hemoglobin chromophore
All vascular lasers rely on selective photothermolysis. The laser emits a wavelength that is preferentially absorbed by oxyhemoglobin (the oxygen-carrying form of hemoglobin in red blood cells). Absorbed energy converts to heat, damaging the vessel wall and causing the vessel to collapse, fibrose, and eventually be reabsorbed by the body.
The key variable is wavelength, because hemoglobin has multiple absorption peaks:
- Around 532 nm: A strong absorption peak. KTP (potassium titanyl phosphate) lasers operate here. High affinity for oxyhemoglobin but very superficial penetration — effective for fine surface vessels and diffuse redness.
- Around 577–595 nm: Another absorption band. Pulsed dye lasers operate at 585 or 595 nm. Slightly deeper penetration than 532 nm, still primarily targeting oxyhemoglobin.
- Around 1064 nm: A minor hemoglobin absorption peak, but with significantly deeper tissue penetration. Nd:YAG lasers operate here. Effective for deeper and larger-caliber vessels, including leg veins and venous malformations, but also safer in darker skin because 1064 nm is less absorbed by epidermal melanin.
The wavelength determines how deep the energy reaches and which vessels it can treat.
Vbeam (Candela): pulsed dye laser
Manufacturer: Candela Corporation (Marlborough, MA), now part of the Candela Medical group. The Vbeam family includes Vbeam Perfecta, Vbeam Prima, and Vbeam Pro.
FDA clearance: The original Vbeam PDL received FDA 510(k) clearance (K033461, 2004). Vbeam Prima received clearance (K183452, 2019) with an additional 1064 nm wavelength. In June 2023, the Vbeam family received expanded clearance (K230990) for pediatric use (birth to 21 years) for port-wine stains and hemangiomas.
Wavelength and depth:
- 595 nm (primary): targets oxyhemoglobin in superficial dermal vessels. Penetration depth approximately 1–2 mm. This is the wavelength used for most rosacea and facial redness treatments.
- 1064 nm (Vbeam Prima only): targets deeper vessels and provides additional capability for venous lakes and wrinkles.
Mechanism: PDL uses a flashlamp-excited organic dye to produce short, high-energy pulses at 595 nm. Candela's Dynamic Cooling Device (DCD) sprays a burst of cryogen onto the skin immediately before each laser pulse, protecting the epidermis and improving comfort.
What it treats: Rosacea (erythema and telangiectasia), port-wine stains, hemangiomas, facial and leg telangiectasia, spider veins, acne, scars, stretch marks, poikiloderma of Civatte, warts, and wrinkles. The 595 nm PDL is considered the gold standard for rosacea and port-wine stains based on decades of clinical use.
Evidence: PDL has the largest evidence base of any vascular laser. A 2024 retrospective study in 112 erythematotelangiectatic rosacea patients found PDL had the lowest adverse event profile compared to narrow-band IPL and broad-band IPL, attributed to its precise hemoglobin targeting. A PMC-published 2025 study comparing PDL, IPL, and radiofrequency in rosacea reported PDL efficacy of 68.9–82.5% in reducing erythema area. In a clinical study cited by Candela, Vbeam treated infants with port-wine stains with an average clearance of 88.6% after one year of treatment.
Purpura risk: PDL's main drawback. At higher fluences, the rapid heating causes vessels to rupture, producing purpura (bruise-like purple discoloration) that can last 7–14 days. Modern PDL protocols with longer pulse durations and lower fluences can reduce or eliminate purpura, but this comes at the cost of requiring more treatment sessions. Patients should be told that purpura is possible and planned around accordingly.
Comfort: The DCD cooling spray provides good epidermal protection. Some patients find the cryogen spray itself startling. The treatment sensation is often described as a rubber-band snap. Downtime beyond purpura is typically limited to mild redness and swelling for a few hours.
Fitzpatrick safety: Vbeam is most commonly used in Fitzpatrick I–III. In darker skin (IV–VI), the 595 nm wavelength has some absorption by melanin, increasing the risk of post-inflammatory hyperpigmentation. Careful cooling and conservative settings are necessary, and some providers prefer to avoid PDL in Fitzpatrick V–VI entirely in favor of 1064 nm Nd:YAG.
Excel V (Cutera): dual-wavelength KTP/Nd:YAG
Manufacturer: Cutera, Inc. (Brisbane, CA). The current generation is Excel V+.
FDA clearance: Excel V received FDA 510(k) clearance (K153671). Excel V+ received subsequent clearance for expanded vascular and pigmented indications.
Wavelengths and depth:
- 532 nm (KTP, LBO-generated in Excel V+): targets oxyhemoglobin at its strongest absorption peak. Very superficial — effective for fine telangiectasia, diffuse redness, and superficial pigmented lesions. Excel V+'s LBO (lithium triborate) crystal produces a true solid-state 532 nm beam that Cutera states has 5× higher oxyhemoglobin affinity than 595 nm.
- 1064 nm (Nd:YAG): penetrates deeper (up to several mm), targeting larger and deeper vessels including leg veins, venous lakes, and periorbital veins. Also used for skin revitalization via the Genesis V handpiece, which delivers micro-pulsed 1064 nm energy for diffuse collagen stimulation.
Mechanism: Excel V uses two separate laser sources (KTP and Nd:YAG) in a single platform, with three operating modes: standard vascular treatment, long-pulse Nd:YAG for deep vessels, and the Genesis V micro-pulse mode for skin revitalization. Contact cooling via a sapphire crystal tip cools the skin before, during, and after each pulse.
What it treats: Rosacea, facial veins, leg veins, port-wine stains, angiomas, poikiloderma, venous malformations, bruising, inflammatory acne, benign pigmented lesions (including melasma/chloasma on label), age spots, scars, and wrinkles. The broad indication set comes from the dual-wavelength capability — 532 nm for superficial, 1064 nm for deep.
Evidence: Clinical studies support Excel V's efficacy for vascular and pigmented lesions. A prospective study published in Cutera's white literature found significant improvement in both redness and pigmentation using sequential large and small spot size treatments. The 532 nm wavelength's higher oxyhemoglobin absorption coefficient is a genuine physical advantage for fine red vessels. However, the peer-reviewed evidence base for rosacea specifically is smaller than PDL's decades-long literature.
Purpura risk: Low. KTP lasers produce purpura much less frequently than PDL at standard treatment settings because the energy delivery is more controlled and the vessel wall is heated more gradually rather than rapidly ruptured. This is a practical advantage for patients who cannot afford visible bruising downtime.
Comfort: The sapphire contact cooling tip provides continuous cooling at the treatment site, which many patients find more tolerable than PDL's intermittent cryogen spray. The provider can select cooling temperatures (5°C, 10°C, 15°C, or 20°C). Some patients describe the sensation as a warm pinch rather than a snap. Deeper treatments with the 1064 nm wavelength can be more uncomfortable.
Fitzpatrick safety: The 1064 nm Nd:YAG wavelength is well-established as safer in darker skin (Fitzpatrick IV–VI) because it has lower melanin absorption and deeper penetration. The 532 nm KTP wavelength is used cautiously in darker skin types. Excel V's ability to switch between wavelengths means the provider can select the safer 1064 nm for patients with more melanin-rich skin.
How they compare
| Vbeam (PDL) | Excel V (KTP/Nd:YAG) | |
|---|---|---|
| Primary wavelength | 595 nm | 532 nm + 1064 nm |
| Mechanism | Pulsed dye laser | KTP + Nd:YAG |
| Depth | ~1–2 mm | 532 nm: superficial; 1064 nm: deep (several mm) |
| Gold standard for | Rosacea, port-wine stains | Fine telangiectasia, leg veins, multi-depth |
| Purpura risk | Moderate (reducible with settings) | Low |
| Cooling | Cryogen spray (DCD) | Sapphire contact tip |
| Comfort | Moderate | Generally higher (continuous cooling) |
| Fitzpatrick I–III | Excellent | Excellent |
| Fitzpatrick IV–VI | Caution (melanin absorption) | 1064 nm safer; 532 nm caution |
| Setup time | ~20 min warmup | <1 min |
| FDA pediatric clearance | Yes (birth–21, PWS/hemangiomas) | No |
The clinical picture: for diffuse facial redness and rosacea erythema, PDL (Vbeam) remains the most-studied modality with the longest track record. For discrete fine telangiectasia (visible thread veins), the 532 nm KTP's higher hemoglobin absorption and Excel V's precision tracing handpiece (Dermastat, 1–2 mm spot) give it a practical edge. For deeper or larger vessels including leg veins, Excel V's 1064 nm Nd:YAG is the appropriate wavelength — Vbeam's 595 nm simply does not penetrate deeply enough. For port-wine stains in infants and children, Vbeam has specific FDA pediatric clearance that Excel V does not carry.
What about rosacea in darker skin?
Rosacea in Fitzpatrick IV–VI is underdiagnosed because erythema is harder to visualize against darker baseline skin tones. When vascular laser treatment is indicated, the 1064 nm Nd:YAG wavelength (available on Excel V and other platforms) is generally preferred because it minimizes melanin absorption and PIH risk. PDL at 595 nm can be used cautiously with extended pulse durations and aggressive cooling, but the risk-benefit ratio shifts.
Some providers use a staged approach: start with conservative 1064 nm treatments to reduce deeper vascular components, then add IPL or KTP for any remaining superficial redness once the deeper vessels are controlled.
Limitations and what these devices cannot do
Vascular lasers are not a cure for rosacea. They reduce the vascular manifestations (redness, visible vessels) but do not address the underlying inflammatory pathway. Rosacea is a chronic condition; maintenance treatments are typically needed every 6–12 months, and patients should remain on whatever topical or oral therapy their dermatologist has prescribed.
Neither device is effective for the phymatous (thickening) subtype of rosacea — that requires surgical or ablative laser debulking.
For pigmentation that is not vascular in origin (melanin-driven hyperpigmentation, sun spots), vascular lasers are the wrong tool. Excel V has FDA clearance for benign pigmented lesions (melanin-targeting) via the 532 nm wavelength, which does have some melanin absorption, but dedicated pigment lasers or IPL are generally more effective for this purpose.
Questions to ask a provider
- Do you have both PDL and KTP/Nd:YAG available, or only one platform? (Having both allows treatment selection based on your presentation rather than what is in the room.)
- Which wavelength do you plan to use, and why?
- How many rosacea/vascular patients have you treated at my Fitzpatrick type?
- What is the risk of purpura at the settings you plan to use, and how should I plan around it?
- How many sessions do you estimate, and what does total cost look like?
Sources
- Candela Corporation. Vbeam Prima 510(k) summary, K230990, 2023. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf23/K230990.pdf
- Candela Corporation. Vbeam PDL 510(k) summary, K033461, 2004. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf3/k033461.pdf
- Candela Medical. Vbeam patient information. https://candelamedical.com/patient/brands/vbeam/
- Cutera. Excel V+ product information and indications for use. https://cutera.com/us-en/products/excel-v-plus/
- Cutera. Excel V 510(k) clearance information. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
- Comparison of the efficacy and safety of PDL, IPL, and RF in erythematotelangiectatic rosacea. PMC, 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12988611/
- High-power 532/1064 nm Nd:YAG laser for skin revitalization and treatment of vascular and pigmented lesions. Cutera white paper. https://www.relightmedical.com/wp-content/uploads/2021/04/excel-V-High-Power-Laser-Whitepaper.pdf
- Tanzi EL, et al. Pulsed dye laser treatment of rosacea. Lasers Surg Med. Various years.
